Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18462780 | 1.00 | ALDH1A1 (0.37) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL9977262 | 0.96 | ALDH1A1 (0.35) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL13447804 | 0.96 | ALDH1A1 (0.35) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL204386 | 0.93 | ALDH1A1 (0.33) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL16001561 | 0.88 | NPC1L1 (0.34) | ALDH1A1SCD5KLKB1 | |
| SCHEMBL205729 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL2706305 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL16016012 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL203341 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL2707411 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 3957/4885TSHR 4853/4885KMT2A 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.